Ma RL, Deng Y, Wang YF, Zhu SY, Ding XS, Sun AJ
For MS patients, this test reveals whether genetic predispositions favor GLP-1 receptor sensitivity (rs6923761 variant), GIPR pathway responsiveness (rs1800437), FTO metabolic regulation (rs9939609), or MC4R satiety signaling (rs17782313)all without examining disease-specific immune genes
This transparent model lets you access personalized therapy without worrying that higher doses will trigger unexpected costs
By Suzanne Fenske, MD, FACOG, ABOIM, MSCP GLP-1 receptor agonist medications, including semaglutide (Ozempic), tirzepatide (Monjaro), and liraglutide (Victoza), are FDA-approved for weight loss and diabetes
Recently, the pharmacotherapy of MASLD mainly focuses on three parts of mechanisms: anti-inflammatory (ASK1 inhibitors), anti-diabetic (GCGR agonists, PPAR agonists), and prevention of lipotoxicity (FXR agonists, FGF21 analogues) (Wei et al., 2024)
Ferrandon, S